BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...STARPegBio Co. Ltd. raised around RMB800 million ($121.6 million) in a pre-IPO round co-led by Yunfeng Capital...
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

...between the company and its shareholders, which include Chinese venture capital firms 3W Partners and Yunfeng Capital...
BioCentury | Nov 30, 2018
Company News

WuXi NextCode investing in genomic sequencing project in Ireland

...led by Ireland Strategic Investment Fund, which contributed $70 million, and included existing investors Temasek, Yunfeng Capital...
BioCentury | Nov 27, 2018
Company News

WuXi NextCode investing in genomic sequencing project in Ireland

...led by Ireland Strategic Investment Fund, which contributed $70 million, and included existing investors Temasek, Yunfeng Capital...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Biodesix Inc. Integrated Diagnostics Inc. 7/9/18 ND ND ND Hybio Pharmaceutical Co. Ltd. (SZSE:300199) / Yunfeng Capital...
BioCentury | Jun 2, 2018
Strategy

Partnering on a mission

...He said the $260 million in committed capital from Arch, 6 Dimensions Capital, Boyu Capital, Yunfeng Capital...
BioCentury | May 25, 2018
Financial News

Chinese newco Brii launches with $260M

...through commercialization and market access. Arch, 6 Dimensions Capital and Boyu Capital led the round. Yunfeng Capital...
BioCentury | May 24, 2018
Company News

Chinese newco Brii launches with $260M

...through commercialization and market access. Arch, 6 Dimensions Capital and Boyu Capital led the round. Yunfeng Capital...
BioCentury | May 11, 2018
Finance

Watching the wave

...CStone’s untranched $260 million financing, which closed on May 9. Fellow new investors Sequoia China, Yunfeng Capital...
BioCentury | May 11, 2018
Financial News

Chinese immuno-oncology play CStone raises $260M

...series B ever for a Chinese biopharma. New investors in the round included Sequoia China, Yunfeng Capital...
Items per page:
1 - 10 of 18
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...STARPegBio Co. Ltd. raised around RMB800 million ($121.6 million) in a pre-IPO round co-led by Yunfeng Capital...
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

...between the company and its shareholders, which include Chinese venture capital firms 3W Partners and Yunfeng Capital...
BioCentury | Nov 30, 2018
Company News

WuXi NextCode investing in genomic sequencing project in Ireland

...led by Ireland Strategic Investment Fund, which contributed $70 million, and included existing investors Temasek, Yunfeng Capital...
BioCentury | Nov 27, 2018
Company News

WuXi NextCode investing in genomic sequencing project in Ireland

...led by Ireland Strategic Investment Fund, which contributed $70 million, and included existing investors Temasek, Yunfeng Capital...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Biodesix Inc. Integrated Diagnostics Inc. 7/9/18 ND ND ND Hybio Pharmaceutical Co. Ltd. (SZSE:300199) / Yunfeng Capital...
BioCentury | Jun 2, 2018
Strategy

Partnering on a mission

...He said the $260 million in committed capital from Arch, 6 Dimensions Capital, Boyu Capital, Yunfeng Capital...
BioCentury | May 25, 2018
Financial News

Chinese newco Brii launches with $260M

...through commercialization and market access. Arch, 6 Dimensions Capital and Boyu Capital led the round. Yunfeng Capital...
BioCentury | May 24, 2018
Company News

Chinese newco Brii launches with $260M

...through commercialization and market access. Arch, 6 Dimensions Capital and Boyu Capital led the round. Yunfeng Capital...
BioCentury | May 11, 2018
Finance

Watching the wave

...CStone’s untranched $260 million financing, which closed on May 9. Fellow new investors Sequoia China, Yunfeng Capital...
BioCentury | May 11, 2018
Financial News

Chinese immuno-oncology play CStone raises $260M

...series B ever for a Chinese biopharma. New investors in the round included Sequoia China, Yunfeng Capital...
Items per page:
1 - 10 of 18